The Hughes Medical Institute, one of the most famous non-profit medical research institutes in the United States, faced the outbreak of global bioterrorism. Under the coordination of the WHO, the Hughes Medical Institute became an 'Angel Team' to develop a specific drug for the VFV virus. of research institute.
Qiu Xiang led the team towards the conference room.
Qiu Xiang now has a report in his hand, a report on VFV antibody research, but there is not much joy on everyone's face.
The use of antibodies in the patient's serum or body fluids to treat viral infections has proven successful and is the most commonly used method. During this period of research, their team found that the antibodies in the patient's serum were too weak to clear the VFV virus.
And they were unable to find patients in the recovery stage. The VFV virus was too virulent, and the antibodies produced by the human body's immune system simply could not 'kill' the virus.
This resulted in their research on specific drugs being at a loss.
After discussion, the team decided to try using animal immune serum. Eight species of animals were recruited for the experiment and the animals were infected with the virus. However, they soon discovered that even the immunized bovine serum had no obvious effect in treating VFV.
During this period, I experimented every day and tried hundreds of possible ways.
They tried all the possible conjectures they discussed, and finally found that the one with the highest probability of success was monoclonal antibodies.
In order to speed up the research, the 72-person team was divided into eight groups. Four groups were responsible for finding other therapeutic drugs, and the remaining four groups were responsible for testing the 16 monoclonal antibodies developed. The team led by Qiu Xiang was one of them.
During the test, all four groups used 1,000 times the LD50 (half lethal dose) to infect experimental mice.
Within 24 hours after exposure, mice were injected with monoclonal antibodies. Of the 16 monoclonal antibodies in four groups, 11 were effective; at 48 hours, 5 antibodies were still effective; at 72 hours, only two antibodies were effective.
It is an antibody studied by the first group led by him, and an antibody studied by the third group led by British medical scientist Judson.
After finding two of the antibodies, they began to experiment with rabbits. After 24 hours, both antibodies were effective. After 48 hours, the capabilities of the monoclonal antibodies began to show obvious differences, and many of them lost their activity. No matter how long the time passed, the effect of the antibodies would be reduced. Getting weaker and weaker.
The incubation period of the VFV virus far exceeds this time. Such antibodies cannot be used for treatment at all, and research has stalled again.
Finally, after everyone's discussion, it was decided to adopt the 'cocktail' method used in EBOR specific drug research, using a mixture of the four most effective monoclonal antibodies, and using a virus that can produce human interferon as an adjuvant for the 'cocktail' antibodies. , so that the 'cocktail' can still work 72 hours after exposure.
The 'cocktail' potion was named AG72 by them.
Now, the test results of AG72 are in Qiu Xiang’s hands.
Looking at the report in his hand, he couldn't be happy because the results were different from what they imagined.
When Qiu Xiang, Judson and others entered the conference room, they felt dozens of pairs of eyes falling on them. Many researchers on the scene looked not very good. Since the formation of the 72-man team, their research has made some progress, but not much. Now all hope lies in the reports in the hands of Qiu Xiang and Judson.
"Come on." Qiu wanted to hand the report to Judson.
"Come on." Judson shook his head and did not reach out to take it.
Qiu Xiang nodded helplessly, and after everyone was seated, he asked his assistant to send the report in his hand to every researcher on the field, and then he walked up to the podium.
"The monoclonal antibody test results came out, and they were different from what we predicted. We tested the effect of AG72 on two rhesus monkeys. On the fourth day of infection, the monkeys showed symptoms, and they were injected with AG72 as planned. But unfortunately, the virus in the monkeys has not disappeared, and there is no cure for VFV." Qiu Xiang said in a heavy voice.
There was a sigh in the conference room, and many experts shook their heads and frowned.
Monoclonal antibodies are the most promising direction for success in a short period of time. If monoclonal antibodies fail, it will take longer for specific drugs to appear.
The number of people infected with the VFV virus worldwide has now reached more than 26,000, and the number is refreshing every day. The death toll has also soared to 2,378, and no case has been cured yet. If treatment drugs are not available, more and more people will die.
"But there is some good news that is not too good."
Everyone immediately cheered up and pricked up their ears, waiting for Qiu Xiang's answer.
"The condition of the rhesus monkeys injected with AG72 did not worsen within a week. AG72 cannot cure the condition of VFV, but it can inhibit the metabolism of VFV and control the further deterioration of the condition. This result can buy more treatment time for the condition .”
Many people on the field clapped excitedly and cried with joy. At this time, any small piece of good news is exciting news.
The 'Angel Team' has made a breakthrough in the development of specific drugs for the VFV virus and successfully developed a monoclonal antibody drug that inhibits the progression of VFV.
When the news was released, it spread like crazy to all corners of the world, arousing excitement among the people.
Now is the most serious period of the VFV virus. At a time of global panic, the biological virus has almost reached the critical point of completely losing control. At this time, good news comes from the 72-man team, which is undoubtedly the most exciting time.
The dawn of victory in this fight against biological warfare has begun.
While the outside world cheered for the results of the 72-man team, there was the same happy event in another corner.
Jianghe Institute of Microbiology and Medicine.
Xu Minsheng had a rare smile on his face.
After Jianghe Company and Lanhong Pharmaceutical were merged by the Marching Ant Group and reorganized into Jianghe Pharmaceutical, he became one of the team leaders of Jianghe Pharmaceutical's pharmaceutical development team, responsible for the development of tumor vaccines.
The current Jianghe Pharmaceutical headquarters is Haixing Company’s main microbial medicine research institute, and Haixing Company’s main drugs are developed from here.
Some time ago, Chen Mo contacted them and told them a research direction. He also gave them some information and asked the team at their institute to produce drugs related to the information. The drugs may be able to reduce the activity of the VFV virus and be helpful in the treatment of VFV.
Now is the most terrifying time when the VFV virus is raging. After receiving Chen Mo's order, the entire research team immediately convened personnel to start developing drugs.
The team concentrated the efforts of the entire institute's elite personnel, thoroughly understood the information given by Chen Mo, studied it in shifts, and finally made progress.
During this period, I contacted Chen Mo several times and asked some questions about the research direction. After several major breakthroughs, I finally completed the required medicine according to Chen Mo's wishes.
They named the drug they developed HX3.
Now the metabolic activity of the VFV virus in the petri dish has been significantly reduced after adding the HX3 agent for 24 hours, and the agent has met Chen Mo's requirements.
"Successful." Xu Minsheng showed a rare smile.
"Successful." Several researchers around him nodded and took a deep breath.
"You compile the report and give it to the boss. I'm going to ask the boss what to do with HX3 next." After saying that, Xu Minsheng turned and left the laboratory.
(End of chapter)